Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISABELA1: Ziritaxestat in Idiopathic Pulmonary Fibrosis
NCT03711162Phase 3Terminated
- Sponsor
- Galapagos NV
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Primary endpoint: Annual Rate of Decline in FVC up to Week 52. Started Nov 2018; status: terminated.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03711162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711162.